Creso Pharma said Wednesday that CLV Frontier Brands Pty, its equal one-third joint venture with UK-based Baltic Beer Company and Canadian TSX Venture, is planning to have its first beers and tonics on sale in Europe and Canada during the summer, with the aim to later expand.
Creso has also announced that the TSX Venture Exchange has conditionally accepted LGC’s joint venture investment in CLV.
Miri Halperin Wernli, Co-Founder and CEO of Creso Pharma said that CLV is seen an exciting business partnership that can add significant sales revenues to Creso Pharma. “Full details of the beer and tonic ranges will be released when CLV debuts its products and branding at a world-wide product launch. Europe will be the initial focus for sales, as Europe is the home market for the Baltic Beer Company’s multi award winning Viru beer. The company also plans to launch in Canada this summer,” said Halpering Wernli.
CLV’s beers contain terpenes, which carry the flavour and aroma of cannabis, but which do not contain THC or CBD or any other cannabinoids. The terpenes are extracted from various plant sources, all of which are food-grade, 100% natural and non-genetically modified (GMO) ingredients. The terpenes are pure, not contaminated with any other ingredient, and safe for human consumption as flavouring and food additive ingredients, meeting the criteria of FDA/FEMA GRAS (Generally Recognized as Safe) for human consumption. The terpenes are introduced to the beer at the post-fermentation stage in much the same manner as hop extracts are added.